Assessing hidden cortisol excess in type 2 diabetes and obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the prevalence of hidden hypercortisolism (HidHyCo) in patients with type 2 diabetes (T2D) and in obese individuals without T2D. It will analyze the clinical characteristics associated with HidHyCo in both groups. Participants aged 18 to 75 years will be recruited from outpatient clinics specializing in diabetes and obesity. The study will involve a 1mg dexamethasone suppression test (DST) to assess cortisol levels.

Why it matters

Who can join: the full rules

Inclusion Criteria:

patients with T2D and Obesity

Exclusion Criteria:

* pregnancy/breast feeding,
* sleep apnea,
* prepuberal onset of hypertension, hormonal hypersecreting adrenal mass,
* symptoms of hypercortisolism;
* already known secondary hypertension;
* conditions associated with increased hypothalamic-pituitary-adrenal (HPA) axis activity, -severe autoimmune/rheumatologic and hematologic diseases, alcoholism, kidney disease (glomerular filtration rate \<60)
* drugs influencing the HPA axis activity. For inclusion in Group 2 the presence of T2D will be an exclusion criteria

Where it's running

• Istituto Auxologico Italiano
  Milan, Italy Recruiting
• Niguarda Hospital
  Milan, Italy Recruiting
• Campus Bio-Medico University
  Roma, Italy Recruiting
• University of Siena
  Siena, Italy Recruiting
• Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine
  Udine, Italy Recruiting

Study contacts

• Study coordinator: Valentina Morelli, PhD
• Email: v.morelli@auxologico.it
• Phone: 02619112547

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• AI-assisted lifestyle plan vs. tirzepatide for obesity with newly diagnosed type 2 diabetes

  This study tests whether an AI-guided lifestyle program can help overweight adults with newly diagnosed type 2 diabetes lose more weight and improve blood sugar control compared with tirzepatide or standard lifestyle care.

  Recruiting at 5 sites Phase 4 The First Affiliated Hospital of Anhui Medical University · Hefei, Anhui and 4 other locations · NCT07697391

• Long-term test of maridebart cafraglutide for obesity and type 2 diabetes

  This extension study tests whether maridebart cafraglutide remains effective and safe for people with obesity and type 2 diabetes who previously completed a parent trial.

  Recruiting at 45 sites Phase 3 Amgen · Gilbert, Arizona and 44 other locations · NCT07684144

• Tirzepatide in real-world Paraguay for obesity and type 2 diabetes

  This study tests tirzepatide in adults in Paraguay to see how it works for weight loss and blood sugar control in everyday clinical practice.

  Recruiting Phase 4 Las Rías Medical Center · Asunción · NCT07588438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.